


PRODUCT: GSK-J4 hydrochloride**ALTERNATE NAME:** Ethyl 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate, monohydrochloride**CATALOG #:** 2259-1, 5**AMOUNT:** 1 mg, 5 mg**STRUCTURE:****MOLECULAR FORMULA:** C₂₄H₂₇N₅O₂·HCl**MOLECULAR WEIGHT:** 454.0**CAS NUMBER:** N/A**APPEARANCE:** White to off-white solid**SOLUBILITY:** DMSO**PURITY:** ≥95%**STORAGE:** At -20°C. Protect from light and moisture**DESCRIPTION:** Cell-permeable. An ethyl ester derivative of the JMJD3 selective histone demethylase inhibitor GSK-J1 (Cat. No. 2260-1, 5) (IC₅₀ > 50 μM in vitro). When administered to human primary macrophages, GSK-J4 can reduce lipopolysaccharide (LPS)-induced proinflammatory cytokine production, most notably including that of TNFα (IC₅₀ = 9 μM).**REFERENCE:** Kruidenier, L. *et al.* (2012). *Nature* **488**, 404-408**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

GSK-J1 sodium salt (Cat. No. 2260-1, 5)

β-Lapachone (Cat. No. 2262-5, 25)

Tranylcypromine hemisulfate (Cat. No. 1816-25, 100)

USAGE: *FOR RESEARCH CH USE ONLY! Not to be used in humans*